MAK Capital reports 7% stake in Evotec SE
Evotec SE received an amended ownership filing from investment entities affiliated with MAK Capital.
Rhea-AI Filing Summary
Evotec SE received an amended ownership filing from investment entities affiliated with MAK Capital. MAK Capital Fund, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 12,503,512 Ordinary Shares, representing 7.0% of Evotec’s Ordinary Shares based on 177,877,782 shares outstanding as of March 30, 2026.
This Amendment No. 1 updates a prior Schedule 13D and notes that the reporting persons sent an April 2 letter to Evotec’s Supervisory and Management Board, filed as an exhibit, in furtherance of their stated purpose for holding the stake.
Positive
- None.
Negative
- None.
Insights
MAK Capital discloses a 7% Evotec stake and engages the board.
Affiliates of MAK Capital report beneficial ownership of 12,503,512 Ordinary Shares of Evotec SE, equal to 7.0% of the company’s Ordinary Shares based on 177,877,782 shares outstanding as of March 30, 2026. This places them among Evotec’s larger shareholders.
The filing is an Amendment No. 1 to a prior Schedule 13D, indicating an ongoing, non-passive investment. The report highlights that the reporting persons have sent an April 2 letter to Evotec’s Supervisory and Management Board, which is attached as an exhibit and tied to their stated purpose of transaction.
The use of a Schedule 13D and direct board communication suggests an engaged shareholder rather than a purely passive holder. Actual implications for strategy or governance depend on the specific points in the April 2 letter and any future responses or changes disclosed in subsequent company communications.
Key Figures
Key Terms
Schedule 13D regulatory
beneficially owned financial
FAQ
What stake in Evotec SE does MAK Capital report in this Schedule 13D/A?
Who are the reporting persons in the Evotec SE (EVO) Schedule 13D/A?
What is the purpose of this Amendment No. 1 to Evotec SE’s Schedule 13D?
What exhibits are included with the Evotec SE (EVO) Schedule 13D/A filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.